Plozalizumab

Drug Profile

Plozalizumab

Alternative Names: Anti-CCR2 monoclonal antibody; MLN-1202; TAK-202

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Millennium Pharmaceuticals; Takeda; Takeda Oncology
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atherosclerosis; Diabetic nephropathies
  • Phase I Malignant melanoma; Solid tumours
  • Discontinued Multiple sclerosis; Rheumatoid arthritis; Scleroderma

Most Recent Events

  • 28 Jul 2017 Phase-I clinical trials in Solid tumours in USA (Parenteral) (3285061; Takeda Q2 report,
  • 15 Dec 2016 Biomarkers information updated
  • 01 Oct 2016 Takeda withdraws a phase I trial in Healthy volunteers prior to enrollment in Japan due to a business decision and no safety or efficacy concerns (NCT02426021)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top